PRESS
2010 - 06 - 01 Complix Luxembourg
Complix NV, a recently founded biopharmaceutical company, announced on June 4, 2010 the successful closing of its Series A financing round, raising €5 million (~US$6.25 million) from a syndicate of leading life sciences investors. The transaction was co-led by Vesalius Biocapital (Luxembourg) and LRM (Belgium), with CRP-Santé (Luxembourg), existing investors and management also participating.
Complix is focused on the discovery and development of next generation drugs based on “Alphabodies”, a novel class of biopharmaceuticals with superior therapeutic potential. Complix also announced the creation of a fully-owned subsidiary in Luxembourg to develop novel Alphabody based therapies against viral diseases in a strategic collaboration with CRP-Santé.
Download the Local Press release:
Download the International Press release: